One-Year Retention Study of Adjunctive Perampanel Treatment in Epilepsy Patients.

abstract：:The objective of this study was to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of five fixed doses of ganstigmine (CHF 2819) in patients with probable Alzheimer's disease (AD). This randomized, double-blind, placebo-controlled trial evaluated five dose levels (5, 7...

journal_title：Clinical neuropharmacology

authors： Jhee SS,Fabbri L,Piccinno A,Monici P,Moran S,Zarotsky V,Tan EY,Frackiewicz EJ,Shiovitz T

更新日期：2003-05-01 00:00:00

abstract：BACKGROUND:Serotonin syndrome is a potentially fatal complication that usually occurs in the combination use of several serotonergic agents. We presented a patient with major depressive disorder under the treatment of bupropion, trazodone, and quetiapine. Serotonin syndrome developed soon after she received the first s...

journal_title：Clinical neuropharmacology

authors： Cheng YC,Liang CM,Liu HC

更新日期：2015-05-01 00:00:00

abstract：OBJECTIVES:Obsessive-compulsive disorder (OCD) is notably a comorbid disorder in patients with schizophrenia. This study aimed to evaluate clinical features and correlates of early onset patients with schizophrenia with OCD. METHODS:In the present study, we included 10 patients with both schizophrenia and OCD and 19 p...

journal_title：Clinical neuropharmacology

authors： Baytunca B,Kalyoncu T,Ozel I,Erermiş S,Kayahan B,Öngur D

更新日期：2017-11-01 00:00:00

abstract：:The treatment of obesity remains a puzzling challenge because long-term maintenance of weight loss--one of the most suitable goals--is rarely achieved with conventional methods. Among the theoretical measures able to maintain a permanent and bearable constraint to obtain the maintenance of weight loss is long-term (li...

journal_title：Clinical neuropharmacology

authors： Guy-Grand BJ

更新日期：1988-01-01 00:00:00

abstract：:The aim of this study was to assess the growth hormone (GH) axis in methylphenidate (MPH)-treated and untreated boys with attention-deficit and hyperactivity disorder (ADHD), by evaluating serum GH, GH-binding protein (GHBP) activity, and insulin-like growth factor I (IGF-I) levels as compared to age-matched normal co...

journal_title：Clinical neuropharmacology

authors： Toren P,Silbergeld A,Eldar S,Laor N,Wolmer L,Koren S,Weitz R,Inbar D,Reiss A,Eshet R,Weizman R

更新日期：1997-06-01 00:00:00

abstract：RATIONALE:Clobazam (CLB) has proven efficacy against multiple seizure types. Although available in many countries, it is not approved by the US Food and Drug Administration. The objective of this study was to evaluate the usage patterns, efficacy, tolerability, and 1-year retention of CLB in patients with refractory ep...

journal_title：Clinical neuropharmacology

authors： Montenegro MA,Arif H,Nahm EA,Resor SR Jr,Hirsch LJ

更新日期：2008-11-01 00:00:00

abstract：:The primary objective of this study was to describe the pharmacokinetics of oral pergolide in patients with mild to moderate Parkinson disease using a new high-performance liquid chromatography-tandem mass spectrometry assay. A secondary objective was to investigate the relationship between plasma concentrations and e...

journal_title：Clinical neuropharmacology

authors： Thalamas C,Rajman I,Kulisevsky J,Lledó A,Mackie AE,Blin O,Gillespie TA,Seger M,Rascol O

更新日期：2005-05-01 00:00:00

abstract：:Deprenyl, a selective inhibitor of monoamine oxidase, type B, which is free of the "tyramine effect," may ameliorate symptom fluctuations in advanced Parkinson's disease (PD). We randomized 96 patients with marked symptom fluctuations at three centers to receive either deprenyl 5 mg b.i.d. or placebo in parallel fashi...

journal_title：Clinical neuropharmacology

authors： Golbe LI,Lieberman AN,Muenter MD,Ahlskog JE,Gopinathan G,Neophytides AN,Foo SH,Duvoisin RC

更新日期：1988-02-01 00:00:00

abstract：OBJECTIVES:The units of different botulinum toxin products are not identical, and the dose equivalence has been debated for several years. In the year 2000, our clinic changed the recommended botulinum toxin product from Botox to Dysport for the treatment of cervical dystonia. Based on published reports, where dose con...

journal_title：Clinical neuropharmacology

authors： Rystedt A,Nyholm D,Naver H

更新日期：2012-11-01 00:00:00

abstract：BACKGROUND:Serotonin syndrome (SS) is a potentially life-threatening condition that can be caused by use of proserotonergic drugs. Several studies have reported that combined administration of various medications may induce SS. We report a case of SS in a patient who was being treated with dopaminergic and noradrenergi...

journal_title：Clinical neuropharmacology

authors： Jeon DG,Kim YW,Kim NY,Park JH

更新日期：2017-07-01 00:00:00

abstract：OBJECTIVE:To determine if levetiracetam is efficacious in the treatment of essential tremor. METHODS:Fifteen patients (3 women), aged 35 to 83 years, with essential tremor were studied in a double-blind, placebo-controlled crossover trial of levetiracetam. During the 2 treatment periods, levetiracetam or placebo was t...

journal_title：Clinical neuropharmacology

authors： Elble RJ,Lyons KE,Pahwa R

更新日期：2007-11-01 00:00:00

abstract：:To evaluate the efficacy and safety of gabapentin in the treatment of muscle cramps, we engaged an open-label trial with a group of 30 patients with frequent (> 5 cramps/week), stable, long-lasting cramps, associated with different diseases. Gabapentin was effective in reducing the frequency and severity of muscle cra...

journal_title：Clinical neuropharmacology

authors： Serrao M,Rossi P,Cardinali P,Valente G,Parisi L,Pierelli F

更新日期：2000-01-01 00:00:00

abstract：OBJECTIVES:Treatment-resistant depression is a common occurrence in clinical practice as well as combination treatment with 2 different antidepressants. In the present case series, we study the effectiveness of the addition of reboxetine, during 12 weeks, to 14 outpatients diagnosed with major depressive disorder, acco...

journal_title：Clinical neuropharmacology

authors： López-Muñoz F,Rubio G,Alamo C,García-García P,Pardo A

更新日期：2006-07-01 00:00:00

abstract：:Transient global amnesia (TGA) has been proposed as a possible adverse effect of sildenafil. There are rare cases in the literature, but none had strong evidence to support. Our case is the first to demonstrate a focal punctate diffusion-weighted imaging lesion at the right hippocampus after the use of sildenafil. Thi...

journal_title：Clinical neuropharmacology

authors： Lin KY,Liu MN,Wang PH,Lau CI

更新日期：2020-03-01 00:00:00

abstract：OBJECTIVES:Aripiprazole and ziprasidone are 2 antipsychotic medications that are relatively devoid of the metabolic adverse effects associated with the second-generation antipsychotics. This study aimed to evaluate the effectiveness of switching to ziprasidone in patients who had insufficient response or intolerance to...

journal_title：Clinical neuropharmacology

authors： Kim SW,Shin IS,Kim JM,Bae KY,Yang SJ,Yoon JS

更新日期：2010-05-01 00:00:00

abstract：:To evaluate two different dosage regimens for albendazole (7.5 mg/kg twice a day or 5.0 mg/kg three times a day), a study was performed in 10 patients with a diagnosis of parenchymal brain cysticercosis. Each patient received both regimens sequentially according to a randomized, crossover design. Blood and urine sampl...

journal_title：Clinical neuropharmacology

authors： Sánchez M,Suástegui R,González-Esquivel D,Sotelo J,Jung H

更新日期：1993-02-01 00:00:00

abstract：:Venlafaxine (VEN) pharmacokinetics and effects on the brain monoamine output were investigated in the context of experimental hepatic encephalopathy (HE). Systemic VEN (10 mg/kg; subcutaneous) was administered to chronic portacaval shunted (PCS) and sham-operated rats. Their neocortical extracellular levels of 5-HT, 5...

journal_title：Clinical neuropharmacology

authors： Wikell C,Bergqvist PB,Hjorth S,Apelqvist G,Björk H,Bengtsson F

更新日期：1998-09-01 00:00:00

abstract：OBJECTIVE:The purpose of this study is to investigate the safety and efficacy of aripiprazole in first-episode drug-naive patients with schizophrenia. METHODS:A total of 45 patients were enrolled in an open-label 12-week study. Dosing was determined by clinical judgment. The main efficacy measure was the Brief Psychia...

journal_title：Clinical neuropharmacology

authors： Takahashi H,Oshimo T,Ishigooka J

更新日期：2009-05-01 00:00:00

abstract：:Newly introduced dopamine agonists, such as ropinirole, may offer advantages compared to such older drugs as bromocriptine in patients with advanced Parkinson's disease (PD) with response oscillations or waning efficacy. Dose equivalence of these two drugs, however, has not been well established, which may complicate ...

journal_title：Clinical neuropharmacology

authors： Giménez-Roldán S,Esteban EM,Mateo D

更新日期：2001-11-01 00:00:00

abstract：:A 56 year-old woman who suffered from parkinsonism, oro-lingual dyskinesia (OLD) and tardive akathisia (TA) due to sulpiride is reported. OLD and TA appeared after sulpiride withdrawal. The patient was successfully treated with tetrabenazine even a mild parkinsonism was present. TA seems to be related with an apparent...

journal_title：Clinical neuropharmacology

authors： López de Munain A,Poza JJ,Gorospe A,Arce A,Martí Massó JF

更新日期：1994-10-01 00:00:00

abstract：OBJECTIVE:There has been an increase in the European and North American schizophrenia literature discussing the high prevalence of metabolic syndrome induced by atypical antipsychotic agents. The aim of this article was to review available data on metabolic syndrome induced by atypical antipsychotic agents in patients ...

journal_title：Clinical neuropharmacology

authors： Bou Khalil R

更新日期：2012-05-01 00:00:00

abstract：:A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia. No risk factors for rhabdomyolysis were found, but the calcium-dependent potassium efflux, normally responsible for membrane hyperpolarization and muscle refractoriness, was severely ...

journal_title：Clinical neuropharmacology

authors： Koren W,Koren E,Nacasch N,Ehrenfeld M,Gur H

更新日期：1998-07-01 00:00:00

abstract：:The standard therapy for myasthenia gravis (MG) includes steroids and immunosuppressants, which have delayed onset of action and significant side effects. Plasmapheresis and intravenous immunoglobulin have been used mostly for the treatment of severe exacerbations. In the present study we examined the use of intraveno...

journal_title：Clinical neuropharmacology

authors： Hilkevich O,Drory VE,Chapman J,Korczyn AD

更新日期：2001-05-01 00:00:00

abstract：:Flumazenil is a benzodiazepine receptor antagonist. It is currently used mainly in the anaesthetic and emergency rooms to reverse the effect of exogenous benzodiazepines. Its use in a variety of experimental animal models and in human neuropsychiatric disorders continues to generate a wealth of information on the poss...

journal_title：Clinical neuropharmacology

authors： Malizia AL,Nutt DJ

更新日期：1995-06-01 00:00:00

abstract：:The authors compared the two portions of the OFF period in patients with Parkinson disease and response fluctuations: time to ON (the latency from levodopa intake to turning ON) and wearing off (time from termination of the beneficial dose effect until the time when the next dose was taken). Time to ON was more than t...

journal_title：Clinical neuropharmacology

authors： Merims D,Djaldetti R,Melamed E

更新日期：2003-07-01 00:00:00

abstract：:Male albino rats received a stereotaxic injection of 6-hydroxydopamine (6-OHDA) into the right substantia nigra. Animals demonstrating contralateral rotations 2 weeks postoperatively with apomorphine (0.5 mg/kg i.p.) were treated with L-Dopa (55 mg/kg i.p.), bromocriptine (2 mg/kg i.p.), or polyethylene glycol (vehicl...

journal_title：Clinical neuropharmacology

authors： Schneider MB,Murrin LC,Pfeiffer RF,Deupree JD

更新日期：1984-01-01 00:00:00

abstract：ABSTRACT:Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in children and adolescents. Methylphenidate (MPH) is one of the most widely used drugs in the treatment of ADHD. Enuresis can occur comorbidly with ADHD. However, enuresis is sometimes seen in patients with ADHD as an adve...

journal_title：Clinical neuropharmacology

authors： Uzun N,Akinci MA,Karatoprak S

更新日期：2021-01-01 00:00:00

abstract：:Seven of 63 children (11%) treated with clobazam (CLB) for refractory epilepsy developed a severe behavior disorder. This disorder was characterized by aggressive agitation, self injurious behavior, insomnia, and incessant motor activity occurring between 10 and 55 days after initiation of drug therapy. The affected c...

journal_title：Clinical neuropharmacology

authors： Sheth RD,Goulden KJ,Ronen GM

更新日期：1994-08-01 00:00:00

abstract：:A 40-year-old man with cervical dystonia developed an acute inflammatory demyelinating polyradiculoneuritis after botulinum toxin type A treatment. Some cases of idiopathic brachial plexopathy and polyradiculoneuritis have been reported to date. Although a causal relationship is not firmly established, the clinical te...

journal_title：Clinical neuropharmacology

authors： Burguera JA,Villaroya T,López-Alemany M

更新日期：2000-07-01 00:00:00

abstract：:There is strong evidence to support the hypothesis that the rapid effects of steroids on neurons are membrane-mediated. Rapid steroid effects have been demonstrated in the absence of intracellular receptors, in the presence of RNA or protein synthesis inhibitors, and in response to steroids coupled to large proteins t...

journal_title：Clinical neuropharmacology

authors： Golden GA,Mason PE,Rubin RT,Mason RP

更新日期：1998-05-01 00:00:00